Open Access Research article

Successful immunotherapy with matrix metalloproteinase-derived peptides in adjuvant arthritis depends on the timing of peptide administration

Jolanda HM van Bilsen, Josée PA Wagenaar-Hilbers, Maarten JF van der Cammen, Mariska EA van Dijk, Willem van Eden and Marca HM Wauben*

Author Affiliations

Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, The Netherlands

For all author emails, please log on.

Arthritis Res 2002, 4:R2  doi:10.1186/ar421

Published: 7 May 2002

Abstract

We have recently found that matrix metalloproteinases (MMPs) are targets for T-cell and B-cell reactivity in experimental arthritis. In the present article, we investigate whether modulation of MMP-specific T-cell responses could influence the course of adjuvant arthritis (AA). Lewis rats were treated nasally with MMP peptides prior to or after AA induction. Administration of the MMP-10 or the MMP-16 peptide prior to AA induction reduced the arthritic symptoms. In contrast, administration of the MMP-10 peptide after AA induction aggravated the arthritic symptoms. The present study shows the possible usefulness of MMP peptides for immunotherapy. However, a clear understanding of proper timing of peptide administration is crucial for the development of such therapies.

Keywords:
adjuvant arthritis; immunotherapy; matrix metalloproteinase; nasal treatment; peptides